Skip to content
DataLookout
Menu

NCT07917390

ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of dose limiting toxicities
Timeframe: first 30 days of treatment with ALT-100
Percentage of participants who achieve a PSA decrease of at least 30%
Timeframe: After up to 6 months of treatment with ALT-100
Percentage of participants who achieve a PSA decrease of at least 50%
Timeframe: After up to 6 months of treatment with ALT-100
Radiographic progression-free survival
Timeframe: After up to 6 months of treatment with ALT-100

Secondary (20)

Maximum plasma concentration of ALT-100
Time to reach maximum plasma concentration of ALT-100
Area under the curve (AUC) up to the last measurable plasma concentration for ALT-100
Area under the curve (AUC) over the dosing interval for ALT-100
Half-life for ALT-100
Show 15 moreShow less
Trough plasma concentration for ALT-100
Average plasma concentration during a dosing interval for ALT-100
Plasma concentration of eNAMPT
Plasma concentration of IL-6
Plasma concentration of IL-8
Plasma concentration of TNF-a
Plasma concentration of IL-1b
Plasma concentration of IL-1RA
Plasma concentration of Ang2
Plasma concentration of VEGF
Plasma concentration of BMP-2
Plasma concentration of PDGF-BB
Plasma concentration of osteopontin
Plasma concentration of osteocalcin
Plasma concentration of bALP

Arms and interventions

Phase 1 - Dose level 1 - 1.0 mg/kg ALT-100Experimental

This is the starting dose for the phase 1 portion of the study.

Phase 1 - Dose Level 2 - 4.0 mg/kg of ALT-100Experimental

This is the second dose level that will be tested in the phase 1 portion of the study.

Phase 2 - Recommended phase 2 dose of ALT-100Experimental

Participants randomized to this arm will receive the recommended phase 2 dose determined in the phase 1 portion of the study.

Phase 2 - Comparator dose of ALT-100Active comparator

Participants randomized to this arm will receive a comparator dose of ALT-100 that is not the recommended phase 2 dose determined in phase 1.

Biologicals: ALT-100